Organization:Bespoke Gene Therapy Consortium

From HandWiki

The Bespoke Gene Therapy Consortium (BGTC) is a research initiative of the US Foundation for the National Institutes of Health.[1][2] The consortium consists of the FDA, NIH, five non-profit organizations, and 10 pharmaceutical companies.[3][4][5]

References

  1. ↑ "Bespoke Gene Therapy Consortium" (in EN). Foundation for the National Institutes of Health. 26 October 2021. https://www.nih.gov/research-training/accelerating-medicines-partnership-amp/bespoke-gene-therapy-consortium. 
  2. ↑ "The AMP Bespoke Gene Therapy Consortium" (in en). Foundation for the National Institutes of Health. 3 January 2022. https://ncats.nih.gov/programs/BGTC. 
  3. ↑ Begley, Anna (2021-10-28). "FDA joins Bespoke Gene Therapy Consortium (BGTC) for rare diseases" (in en). European Pharmaceutical Review. European Pharmaceutical Review (Russell Publishing Limited). https://www.europeanpharmaceuticalreview.com/news/164721/fda-joins-bespoke-gene-therapy-consortium-bgtc-for-rare-diseases/. 
  4. ↑ "NIH and FDA Lead Coalition to Accelerate Gene Therapy Development for Rare Diseases". BioPharm International. BioPharm International (MJH Life Sciences and BioPharm International). 2021-10-29. https://www.biopharminternational.com/view/nih-and-fda-lead-coalition-to-accelerate-gene-therapy-development-for-rare-diseases. 
  5. ↑ Schneider, M.D., Christian K (2021-12-01). "FDA Keeps New Drugs Coming". PharmExec. Pharmaceutical Executive (MJH Life Sciences and Pharmaceutical Executive) 41 (12). https://www.pharmexec.com/view/fda-keeps-new-drugs-coming. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Organization:Bespoke_Gene_Therapy_Consortium&oldid=2783307"